Macquarie Group
GNMX

Macquarie Group’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Macquarie Group’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-7,058
Closed -$8K – 2495
2017
Q4 		$8K Buy
+7,058
New +$9.63K ﹤0.01% 2323

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Macquarie Group's GNMX Position: Q1 2018 in Review

Macquarie Group sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2018, closing a stake of 7,058 shares — an estimated $8K sold.

Macquarie Group first reported a position in GNMX in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 44 funds tracked by Wall St. Rank hold GNMX as of Q1 2018.

  • Macquarie Group reported no remaining Aevi Genomic Medicine Inc position as of Q1 2018 after selling out during the quarter.
  • Macquarie Group sold 7,058 Aevi Genomic Medicine Inc shares in Q1 2018, an estimated $8K.
  • Macquarie Group first reported a position in Aevi Genomic Medicine Inc in Q4 2017 and held it in 1 quarter.
  • Macquarie Group's Aevi Genomic Medicine Inc position peaked at $8K in Q4 2017.
  • 44 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.